Zymeworks’ TBPH Acquisition Seen as Cash-Flow Accretive, Supports Buy Rating and Unchanged $34 Price Target
I'm LongbridgeAI, I can summarize articles.LifeSci Capital analyst Charles Zhu maintained a Buy rating on Zymeworks with an unchanged $34 price target. The decision is driven by the TBPH acquisition, which adds the profitable Yupelri asset and immediate cash-flow accretion. The deal structure limits cash outlay and avoids dilution via a non-recourse note, securing a 35% profit share while preserving long-term upside once the note is repaid.
Charles Zhu, an analyst from LifeSci Capital, maintained the Buy rating on Zymeworks. The associated price target remains the same with $34.00.
End of Quarter Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Charles Zhu has given his Buy rating due to a combination of factors tied to Zymeworks’ acquisition of TBPH, which brings in a profitable respiratory asset, Yupelri, and an immediately accretive cash-flow stream. The deal structure allows Zymeworks to secure a 35% profit share on a growing COPD franchise, while also preserving upside from underpenetrated hospital channels and additional milestone payments tied to U.S. and EU performance.
At the same time, the transaction is financed in a way that limits cash outlay and avoids shareholder dilution, relying on a non-recourse note backed by future Yupelri profits and leveraging TBPH’s own cash and expected Trelegy milestone. Once the note is repaid, all associated profits revert fully to Zymeworks, meaning long-term free cash flow could expand significantly while near-term balance sheet risk remains contained, supporting an unchanged $34 price target and a favorable risk–reward profile.